CION Ameerpet
Living with HIV raises the risk of certain lymphomas — but effective antiretroviral therapy has changed the picture dramatically, and HIV-related lymphoma is now often curable. This guide explains the link, the types of aids related lymphoma, and how CION's team treats it.
If you are living with HIV and have just learned that lymphoma is more common in people with the virus, it is natural to feel anxious. The link is real, but it is also far better understood — and far more treatable — than it was two decades ago. Certain lymphomas are recognised as AIDS-defining cancers, which is why the connection between hiv and lymphoma is taken so seriously.
The increased risk comes mainly from chronic immune suppression. When HIV lowers the CD4 count, the immune system loses some of its ability to keep abnormal B-cells and cancer-linked viruses in check. Co-infection with viruses such as Epstein-Barr virus (EBV) and human herpesvirus-8 then drives the uncontrolled growth of lymphoma cells. This is the same broad theme that connects several viral and immune causes of lymphoma explored across our Lymphoma hub.
The most important, hopeful message is this: effective antiretroviral therapy has substantially lowered the incidence of AIDS-related lymphoma, and people living with HIV can now be treated with the same curative intent as anyone else. This page explains the risk clearly, the types of lymphoma involved, and how CION's team plans lymphoma treatment in Hyderabad for people living with HIV.
Since effective combination antiretroviral therapy (ART) became widely available, the incidence of AIDS-related non-Hodgkin lymphoma has fallen dramatically — large population studies report a decline of roughly half or more in the ART era compared with the years before it. ART works by restoring CD4 counts and controlling the chronic immune activation that fuels these cancers. (Source: population cancer-incidence data in people with HIV, as summarised in NCCN and ESMO lymphoma guidance.)
Most HIV-related lymphomas are aggressive B-cell non-Hodgkin lymphomas. The exact subtype — confirmed on a biopsy with markers such as CD20, CD30 and MYC — decides the treatment plan.
The most common lymphoma in people living with HIV. It is an aggressive but highly treatable B-cell lymphoma. Most cases are CD20-positive, which means they respond to an anti-CD20 monoclonal antibody given with chemotherapy. It can appear in unusual sites such as the gut or bone marrow more often than in HIV-negative patients.
A very fast-growing B-cell lymphoma that is over-represented in HIV, often EBV-driven and associated with the MYC marker. Because it grows quickly, it needs prompt diagnosis and intensive treatment — but it is also one of the most curable lymphomas when treated promptly and completely.
A lymphoma that starts in the brain, seen almost exclusively at very low CD4 counts and strongly linked to EBV. It can cause confusion, weakness or seizures. Read more on our dedicated primary CNS lymphoma page — new neurological symptoms warrant urgent brain imaging.
Hodgkin lymphoma is more common in people with HIV, though it is not formally "AIDS-defining". Two rare types — primary effusion lymphoma and plasmablastic lymphoma — are closely tied to HIV and to human herpesvirus-8. All are diagnosed on tissue and treated according to subtype.
HIV is the most striking example of how a weakened or overstimulated immune system can raise lymphoma risk, but it is not the only one. Understanding where HIV sits among these factors can help put your own risk in perspective:
Importantly, having a risk factor does not mean you will develop lymphoma — most people with HIV never do, and controlling the virus lowers the odds further. It is also worth knowing that lymphoma itself is not contagious; it is the underlying viral infections, not the cancer, that can be transmitted.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Worried about your lymphoma risk with HIV, or newly diagnosed and want a plan that coordinates cancer care with your HIV treatment? CION's haemato-oncology team is here — confidentially.
The most powerful thing you can do to reduce your risk of HIV-related lymphoma is to stay on effective antiretroviral therapy (ART). ART restores the CD4 count and suppresses the virus, which rebuilds the immune surveillance that keeps abnormal B-cells and cancer-linked viruses in check.
This is why CION plans HIV-related lymphoma care as a genuine partnership with your HIV team — never as two treatments running in isolation.
Diagnosis follows the same careful, step-by-step pathway as for anyone with suspected lymphoma, with extra attention to HIV status and CD4 count. CION delivers the imaging, biopsy coordination and tissue testing directly.
A biopsy of an affected lymph node or organ is the only way to confirm lymphoma and identify the exact subtype. The tissue is tested for markers such as CD20, CD30 and MYC, and for EBV, which together classify the tumour and guide therapy — for example, CD20 positivity indicates a lymphoma likely to respond to an anti-CD20 monoclonal antibody.
Imaging — often a PET-CT — shows how far the lymphoma has spread and helps set the stage. Because HIV-related lymphomas more often involve the bone marrow, gut or brain, a bone-marrow examination and, where CNS involvement is suspected, brain imaging and spinal-fluid testing may be added.
Your CD4 count and viral load are checked as part of planning, because they influence both the choice of treatment and the supportive care needed. The whole picture is reviewed by CION's multidisciplinary tumour board, working with your HIV physician, before a plan is finalised.
The single biggest change in this field is that people living with HIV are now treated with curative intent, to the same standard as HIV-negative patients — provided the HIV is managed alongside. The main building blocks, all reviewed by the tumour board, are:
Chemotherapy remains the backbone of treatment for aggressive lymphomas, and CION's medical oncology team delivers it directly. Antiretroviral therapy is generally continued alongside, with careful attention to drug interactions and to preventing infection while the immune system is under pressure. Specific regimen names and schedules are covered on our Lymphoma Treatment in Hyderabad page.
For CD20-positive B-cell lymphomas, an anti-CD20 monoclonal antibody is added to chemotherapy — a form of immunotherapy that CION delivers in-house. The decision is guided by the tissue markers found on your biopsy.
Where indicated, precision radiation therapy (IMRT) is delivered directly. Infection prophylaxis, growth-factor support, and survivorship and rehabilitation care are all managed in-house. Where a stem-cell transplant is needed for relapsed disease, it is coordinated through an accredited partner facility — never described as an in-house service.
With modern combined care, people living with HIV can achieve lymphoma outcomes approaching those of HIV-negative patients. Across published series, Hodgkin lymphoma survival is often in the region of 80–90% and diffuse large B-cell lymphoma around 60–70%. These figures vary considerably by individual — by subtype, stage, CD4 count and how well the HIV is controlled — so they are a general guide, not a prediction for any one person. (Source: published lymphoma survival data, as referenced in NCCN and ESMO guidance.)
The outlook for HIV-related lymphoma has transformed. Many people are now cured, and — with well-controlled HIV — outcomes can approach those of people without HIV. The most useful steps you can take are practical ones:
CION offers a dedicated, free written second-opinion service, and care built around healing rather than billing — with transparent costs explained up front. To talk it through with a CION lymphoma specialist, book a free consultation or call 18002028726.
Get a free, confidential written second opinion from CION's haemato-oncology tumour board — with your cancer care coordinated alongside your HIV treatment.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Yes. People living with HIV have a meaningfully higher risk of developing certain lymphomas than the general population, which is why some are classed as AIDS-defining cancers. The extra risk comes mainly from chronic immune suppression (a low CD4 count) and from co-infection with viruses such as Epstein-Barr virus (EBV). Effective antiretroviral therapy has substantially lowered — though not removed — this risk over the last two decades. The lymphomas most linked to HIV are aggressive B-cell types, including diffuse large B-cell lymphoma and Burkitt lymphoma, and, in the brain, primary CNS lymphoma. If you are HIV-positive and notice a persistent swelling or unexplained symptom, ask for prompt evaluation.
AIDS-related lymphoma is a group of lymphomas that occur in people living with HIV, usually when the immune system is significantly weakened. Most are aggressive non-Hodgkin B-cell lymphomas — diffuse large B-cell lymphoma and Burkitt lymphoma are the commonest — and the brain-based form is primary CNS lymphoma. Hodgkin lymphoma also occurs more often in people with HIV, though it is not formally "AIDS-defining". These cancers tend to present at a more advanced stage and in unusual sites (bone marrow, gut, brain) more often than in HIV-negative patients. The good news is that, with modern combined care, outcomes for aids related lymphoma have improved dramatically. Treatment is planned on our Lymphoma Treatment in Hyderabad page.
The pattern of hiv and lymphoma centres on aggressive B-cell non-Hodgkin lymphomas. Diffuse large B-cell lymphoma (DLBCL) is the most frequent. Burkitt lymphoma is over-represented compared with the general population. Primary CNS lymphoma, which starts in the brain and is strongly EBV-driven, is seen almost exclusively at very low CD4 counts. Two rarer types — primary effusion lymphoma and plasmablastic lymphoma — are closely tied to HIV and to human herpesvirus-8. Hodgkin lymphoma is also more common. The exact subtype is confirmed on a biopsy with tissue markers such as CD20, CD30 and MYC, which then guides the treatment plan.
Yes — this is one of the most important messages of the last twenty years. Since effective combination antiretroviral therapy (ART) became widespread, the incidence of AIDS-related lymphoma has fallen substantially, because ART restores CD4 counts and controls the chronic immune activation that drives these cancers. Staying on ART with a suppressed viral load and a healthy CD4 count is the single best way to reduce your risk. ART is generally continued during lymphoma treatment, in close coordination between the HIV physician and the oncology team, and this combined approach is linked to better outcomes. Risk is lowered, not eliminated, so ongoing awareness of symptoms and routine follow-up still matter.
People living with HIV are now treated with the same intent as HIV-negative patients — the goal is remission, not merely control. Treatment usually combines chemotherapy with an anti-CD20 monoclonal antibody for CD20-positive B-cell lymphomas, given alongside continued antiretroviral therapy and preventive medicines against infection. CION delivers chemotherapy, immunotherapy/antibody therapy, targeted therapy and radiation (IMRT) directly, and every case is reviewed by a multidisciplinary tumour board. Where a stem-cell transplant is needed, it is coordinated through an accredited partner facility. Close teamwork between the oncologist and the HIV physician is essential. Specific regimen names and schedules are covered on our Lymphoma Treatment in Hyderabad page.
Outcomes have improved dramatically in the antiretroviral era, and many people with HIV-related lymphoma are now cured. Broadly, published series report Hodgkin lymphoma survival in the region of 80–90% and diffuse large B-cell lymphoma around 60–70%, per NCCN and ESMO-referenced data — and, with well-controlled HIV, people living with HIV can achieve outcomes approaching those of HIV-negative patients. That said, figures vary considerably by individual, depending on the subtype, stage, CD4 count, how well the HIV is controlled and overall health, so no single number predicts one person's outlook. Your treating team can give a realistic estimate for your situation. Book a free consultation to discuss yours.
For anyone, and especially if you are living with HIV, certain symptoms deserve prompt evaluation: a painless, persistent swollen lymph node in the neck, armpit or groin that lasts more than a couple of weeks; drenching night sweats; unexplained weight loss; and persistent fevers not explained by infection. New neurological symptoms — confusion, personality change, weakness or seizures — warrant urgent brain imaging because of the risk of primary CNS lymphoma. These symptoms have many causes and most are not cancer, but in the setting of HIV they should never be ignored. See the Lymphoma hub for the full symptom picture, and speak to a CION lymphoma specialist if they persist.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.